Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ-0,39
KB0,43
PKN121121,70,75
Msft1,16
IBM0,73
DCX68,3368,36-0,84
PFE0,50
21.10.2017 0:34:14
Indexy online
AD Index online
select
AD Index online
 

  • 20.10.2017 20:48:14
22nd Century Group (Stuttgart)
Poslední obchod Změna (%) Změna (EUR) Objem obchodů (EUR)
2,33 2,41 0,06 67
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 21.10.2017
Popis společnosti
Obecné informace
Název společnosti22nd Century Group Inc
TickerXXII
Kmenové akcie:Ordinary Shares
RICXXII.K
ISINUS90137F1030
Prioritní akcieConv. Pref. Shrs
Poslední známé roční výsledky31.12.2016
Poslední známé čtvrtletní výsledky30.6.2017
Počet zaměstnanců k 31.12.2016 46
Akcie v oběhu k 9.8.2017 102 760 340
Počet akcionářů k 31.12.2016 97
MěnaUSD
Kontaktní informace
Ulice9530 Main St
MěstoCLARENCE
PSČ14031-1915
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon17 162 701 523
Fax17168773064

Business Summary: 22nd Century Group, Inc. is a plant biotechnology company. The Company is focused on technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and levels of cannabinoids in cannabis plants through genetic engineering and plant breeding. It is engaged in various activities, including research and development of less harmful or modified risk tobacco products and tobacco plant varieties; development of X-22, a smoking cessation aid consisting of very low nicotine (VLN) cigarettes; manufacture, marketing and distribution of its RED SUN and MAGIC cigarettes; production of SPECTRUM research cigarettes for the National Institute on Drug Abuse (NIDA); contract manufacturing of third-party branded tobacco products, and research and development of plant varieties of hemp/cannabis, such as plants with low to no amounts of delta-9-tetrahydrocannabinol (THC), plants with high levels of cannabidiol (CBD), and other non-THC cannabinoids.
Financial Summary: BRIEF: For the six months ended 30 June 2017, 22nd Century Group Inc revenues increased 5% to $6.1M. Net loss decreased 3% to $6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Gain (loss) on investment increase from $142K (expense) to $346K (income), Sales and Marketing Costs ( including St decrease of 46% to $506K (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Environmental Biotechnology
RBSS2004Investment Trusts
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
NAICSOffices of Other Holding Companies
SICCigarettes
SICCommercial Physical Research
SICHolding Companies, Nec



  • Poslední aktualizace: 21.10.2017
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorHenry Sicignano482.3.201525.1.2011
Chief Financial Officer, TreasurerJohn Brodfuehrer581.4.20131.4.2013
Vice President, General Counsel, SecretaryThomas James5712.5.201412.5.2014
Vice President - Plant BiotechnologyPaul Rushton5330.10.201530.10.2015
Vice President - Research & DevelopmentMichael Moynihan63